Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform Dystrophy Complicated with Choroidal Neovascularization: A Case Report
Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform Dystrophy Complicated with Choroidal Neovascularization: A Case Report
Adult-onset foveomacular vitelliform dystrophy (AOFVD) is a rare disease characterized by accumulation of yellowish deposits in the macula. Rarely, it may be complicated by choroidal neovascularization (CNV). Cases with CNV may be confused with occult CNV in age-related macular degeneration. In our case, we will present the visual and anatomical results of a patient with AOVF-related CNV, in which we administered 3 doses of intravitreal ranibizumab (IVR). A 59-year-old female patient, who attended our clinic with the complaint of decreased vision in both eyes, was diagnosed with AOVF-related CNV in both eyes and was treated with 3 doses of IVR for 3 months. Despite the improvement in visual and anatomical functions 1 month after the first dose, vision decreased, and anatomical functions regressed to the pre-injection state in continued injections. IVR therapy is not an appropriate treatment option in the treatment of AOVF-associated CNV.
Keywords:
anti-VEGF – optic coherence tomography – adult onset vitelliform dystrophy – retinal dystrophy – subretinal deposits
Autoři:
Mustafa Berhuni 1
; Nesime Setge Tıskaoğlu 1
; Cem Öztürkmen 2
Působiště autorů:
Ersin Arslan Research and Education Hospital, Gaziantep, Turkey
1; Goznuru Eye Hospital, Gaziantep, Turkey
2
Vyšlo v časopise:
Čes. a slov. Oftal., 81, 2025, No. 1, p. 38-40
Kategorie:
Kazuistika
doi:
https://doi.org/10.31348/2024/21
Souhrn
Adult-onset foveomacular vitelliform dystrophy (AOFVD) is a rare disease characterized by accumulation of yellowish deposits in the macula. Rarely, it may be complicated by choroidal neovascularization (CNV). Cases with CNV may be confused with occult CNV in age-related macular degeneration. In our case, we will present the visual and anatomical results of a patient with AOVF-related CNV, in which we administered 3 doses of intravitreal ranibizumab (IVR). A 59-year-old female patient, who attended our clinic with the complaint of decreased vision in both eyes, was diagnosed with AOVF-related CNV in both eyes and was treated with 3 doses of IVR for 3 months. Despite the improvement in visual and anatomical functions 1 month after the first dose, vision decreased, and anatomical functions regressed to the pre-injection state in continued injections. IVR therapy is not an appropriate treatment option in the treatment of AOVF-associated CNV.
Štítky
OftalmologieČlánek vyšel v časopise
Česká a slovenská oftalmologie
2025 Číslo 1
- Stillova choroba: vzácné a závažné systémové onemocnění
- Diagnostický algoritmus při podezření na syndrom periodické horečky
- Citikolin jako užitečný pomocník v léčbě diabetické retinopatie a glaukomu
- Normotenzní glaukom: prevalence a zásady terapie
- Familiární středomořská horečka
Nejčtenější v tomto čísle
- Dlhodobé refrakčné a topografické zmeny u očí s keratokónusom po akcelerovanom rohovkovom cross-linkingu
- Chirurgické řešení rhegmatogenního odchlípení sítnice na jediném vidoucím oku
- Intravitreální implantát dexamethasonu v léčbě diabetického makulárního edému se zaměřením na roli OCT biomarkerů
- Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform Dystrophy Complicated with Choroidal Neovascularization: A Case Report